Double-expressor lymphomas (DEL: Myc positive ≥40% and Bcl2 + in >50% by IHC) account for 40% of newly diagnosed DLBCL and 50% of relapsed refractory DLBCL. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.